1)本庄 恵:緑内障の新薬1:ROCK阻害薬.あたらしい眼科32:775-781, 2015
2)井上俊洋:ROCK阻害薬の基礎.眼科58:1461-1469,2016
3)Tanihara H, Inoue T, Yamamoto T et al:One-year clinical evaluation of 0.4% ripasudil(K-115)in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol 94:e26-34, 2016
4)吉谷栄人・坂田 礼・沼賀二郎・他:緑内障患者に対するリパスジル塩酸塩水和物点眼液の眼圧下降効果と安全性の検討.あたらしい眼科33:1187-1190,2016
5)Tanihara H, Inoue T, Yamamoto T et al:Additive intraocular pressure-lowering effects of a rho kinase inhibitor, ripasudil(K-115)combined with timolol or latanoprost. JAMA Ophthalmol 133:755-761, 2015
6)Skaat A, Jasien JV, Ritch R:Efficacy of topically administered rho-kinase inhibitor AR-12286 in patients with exfoliation syndrome and ocular hypertension or glaucoma. J Glaucoma 25:e807-814, 2016
7)Honjo M, Tanihara H, Inatani M et al:Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 42:137-144, 2011
8)Sato S, Hirooka K, Narita E et al:Additive intraocular lowering effects of the rho kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther 33:1628-1634, 2016
9)Rulo AH, Greve EL, Geijssen HC et al:Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmolgy 103:1276-1282, 1996
10)Tamada Y, Taniguchi T, Murase H et al:Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. J Ocul Pharmacol Ther 17:19-25, 2001
11)Seibold LK, Kahook MY:The diurnal and nocturnal effect of travoprost with SofZia on intraocular pressure and ocular perfusion pressure. Am J Ophthalmol 157:44-49, 2014
12)Isobe T, Mizuno K, Kaneko Y et al:Effects of K-115, a Rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res 39:813-822, 2014